Supplements vergleichen

Prescription-only, clinician-titrated, subcutaneous once daily. Diabetes (Victoza): escalate 0.6 → 1.2 → 1.8 mg/day. Weight management (Saxenda): escalate weekly to 3.0 mg/day. DO NOT self-dose.

Any time

Subkutane Injektion einmal täglich (Victoza bei Diabetes, Saxenda zur Gewichtskontrolle)

Investigational — NO approved dose. Phase-2 trials used once-weekly subcutaneous injection with stepwise escalation up to 4.8-6.0 mg maintenance. There is no approved regimen; do not self-dose an unapproved drug.

Any time

Einmal wöchentliche subkutane Injektion (nur in Erprobung)

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Prior serious hypersensitivity to liraglutide or any GLP-1 receptor agonist

• Insulin and sulfonylureas
• Oral medications (general)
• Other GLP-1 receptor agonists

• Not a dietary supplement and not an approved drug — investigational; do not self-source grey-market vials
• Personal/family history of medullary thyroid carcinoma or MEN 2 (expected GLP-1-class thyroid C-cell warning)
• History of pancreatitis

• Oral medications (delayed gastric emptying)
• Insulin / insulin secretagogues (sulfonylureas)
• Other GLP-1 / incretin drugs